Alglucerase (Ceredase).
Wiltink
E H
EH
Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, Nieuwegein, The Netherlands.
Hollak
C E
CE
D002384:Catalysis; D002518:Ceramides / Q000378:metabolism; D003362:Cost-Benefit Analysis; D005776:Gaucher Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005947:Glucose / Q000378:metabolism; D005962:Glucosylceramidase / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005963:Glucosylceramides / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007262:Infusions, Intravenous; D008099:Liver / Q000166:cytology / Q000187:drug effects; D008264:Macrophages / Q000166:cytology / Q000187:drug effects; D011358:Product Surveillance, Postmarketing; D014018:Tissue Distribution
D002518:Ceramides; D005963:Glucosylceramides; C070292:alglucerase; D005962:Glucosylceramidase; D005947:Glucose